Literature DB >> 12230296

Hypertension in the elderly.

M Pestana1.   

Abstract

Both systolic and diastolic blood pressure increase with advanced age and more than 50% of hypertensive patients are aged above 65 years. Age-related vascular and neuro-humoral changes are important factors leading to the development of hypertension in the elderly and the increase in systolic and diastolic blood pressure with age in any individual is a consequence of the relative change in arterial resistance and stiffness. Therefore, hypertension is predominantly or purely systolic in the elderly both in women and men. The risks of hypertensive patients over the age of 65 years are significant and several trials have provided compelling evidence that treatment of hypertension in the elderly is beneficial in terms of reduced morbidity and mortality. Goal blood pressure should be similar in older and younger patients. Lifestyle modifications are of proven benefit and may be the only therapy needed for stage 1 hypertension. The Sixth report of the JNC recommends diuretics, specifically thiazide diuretics as the initial choice for the treatment of elderly patients without any comorbid conditions. Beta-blockers are less effective than thiazides as first line treatment and may only reduce stroke events. Recently, dihydropiridine calcium antagonists have been advocated as first choice agents for the treatment of hypertension in the elderly and are suitable alternatives when diuretics are ineffective, contraindicated or not tolerated. Newer drugs such as AT1 antagonists are also effective in lowering blood pressure in the elderly but large scale data concerning their protective effects are still lacking.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12230296     DOI: 10.1023/a:1019552602793

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  34 in total

1.  1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee.

Authors: 
Journal:  J Hypertens       Date:  1999-02       Impact factor: 4.844

Review 2.  Drug treatment of hypertension: the reduction of pulse pressure does not necessarily parallel that of systolic and diastolic blood pressure.

Authors:  M E Safar; A Rudnichi; R Asmar
Journal:  J Hypertens       Date:  2000-09       Impact factor: 4.844

3.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

Review 4.  Stiffness of carotid artery wall material and blood pressure in humans: application to antihypertensive therapy and stroke prevention.

Authors:  M E Safar; J Blacher; J J Mourad; G M London
Journal:  Stroke       Date:  2000-03       Impact factor: 7.914

5.  Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group.

Authors:  L Liu; J G Wang; L Gong; G Liu; J A Staessen
Journal:  J Hypertens       Date:  1998-12       Impact factor: 4.844

6.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

7.  Effects of treatment on morbidity in hypertension. 3. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects.

Authors: 
Journal:  Circulation       Date:  1972-05       Impact factor: 29.690

8.  Essential hypertension in the elderly: haemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels.

Authors:  F H Messerli; K Sundgaard-Riise; H O Ventura; F G Dunn; L B Glade; E D Frohlich
Journal:  Lancet       Date:  1983-10-29       Impact factor: 79.321

9.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

10.  Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review.

Authors:  F H Messerli; E Grossman; U Goldbourt
Journal:  JAMA       Date:  1998-06-17       Impact factor: 56.272

View more
  5 in total

1.  Oxidative stress alters renal D1 and AT1 receptor functions and increases blood pressure in old rats.

Authors:  Gaurav Chugh; Mustafa F Lokhandwala; Mohammad Asghar
Journal:  Am J Physiol Renal Physiol       Date:  2010-10-13

Review 2.  Renal dopaminergic system: Pathophysiological implications and clinical perspectives.

Authors:  Marcelo Roberto Choi; Nicolás Martín Kouyoumdzian; Natalia Lucía Rukavina Mikusic; María Cecilia Kravetz; María Inés Rosón; Martín Rodríguez Fermepin; Belisario Enrique Fernández
Journal:  World J Nephrol       Date:  2015-05-06

3.  Age-related hypertension and salt sensitivity are associated with unique cortico-medullary distribution of D1R, AT1R, and NADPH-oxidase in FBN rats.

Authors:  Indira Pokkunuri; Gaurav Chugh; Imran Rizvi; Mohammad Asghar
Journal:  Clin Exp Hypertens       Date:  2015-01-06       Impact factor: 1.749

4.  Altered functioning of both renal dopamine D1 and angiotensin II type 1 receptors causes hypertension in old rats.

Authors:  Gaurav Chugh; Mustafa F Lokhandwala; Mohammad Asghar
Journal:  Hypertension       Date:  2012-03-12       Impact factor: 10.190

5.  Factors Affecting Hypertension among the Malaysian Elderly.

Authors:  Sima Ataollahi Eshkoor; Tengku Aizan Hamid; Suzana Shahar; Chee Kyun Ng; Chan Yoke Mun
Journal:  J Cardiovasc Dev Dis       Date:  2016-03-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.